- Home
- ONVO vs VIRX Comparison
ONVO vs VIRX Comparison
Compare ONVO & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- VIRX
- Stock Information
- Founded
- ONVO 2007
- VIRX 2007
- Country
- ONVO United States
- VIRX United States
- Employees
- ONVO N/A
- VIRX N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONVO Health Care
- VIRX Health Care
- Exchange
- ONVO Nasdaq
- VIRX Nasdaq
- Market Cap
- ONVO 6.5M
- VIRX 7.0M
- IPO Year
- ONVO N/A
- VIRX N/A
- Fundamental
- Price
- ONVO $0.39
- VIRX $0.17
- Analyst Decision
- ONVO
- VIRX Buy
- Analyst Count
- ONVO 0
- VIRX 4
- Target Price
- ONVO N/A
- VIRX $5.00
- AVG Volume (30 Days)
- ONVO 243.5K
- VIRX 2.3M
- Earning Date
- ONVO 02-06-2025
- VIRX 03-06-2025
- Dividend Yield
- ONVO N/A
- VIRX N/A
- EPS Growth
- ONVO N/A
- VIRX N/A
- EPS
- ONVO N/A
- VIRX N/A
- Revenue
- ONVO $103,000.00
- VIRX N/A
- Revenue This Year
- ONVO $59.08
- VIRX N/A
- Revenue Next Year
- ONVO $18.24
- VIRX N/A
- P/E Ratio
- ONVO N/A
- VIRX N/A
- Revenue Growth
- ONVO N/A
- VIRX N/A
- 52 Week Low
- ONVO $0.32
- VIRX $0.13
- 52 Week High
- ONVO $1.74
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- ONVO 47.81
- VIRX 44.76
- Support Level
- ONVO $0.34
- VIRX $0.15
- Resistance Level
- ONVO $0.51
- VIRX $0.19
- Average True Range (ATR)
- ONVO 0.06
- VIRX 0.03
- MACD
- ONVO -0.00
- VIRX -0.00
- Stochastic Oscillator
- ONVO 30.00
- VIRX 21.00
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.